Serum after nebivolol lowers senescence markers in human cells
In a six-week randomized trial involving 71 people with newly diagnosed hypertension, serum after nebivolol produced more consistent benefits in laboratory cells than serum after two other drugs.
Limit: Effects were tested on cultured laboratory cells rather than measuring patient vascular senescence
Edited by Boris Djordjevic · AgingResearch.News
An experiment in human umbilical vein endothelial cells—cells lining the vein in the umbilical cord—tested blood serum from 71 people with newly diagnosed primary hypertension. In a randomized trial, participants received amlodipine, nebivolol or perindopril for six weeks. Researchers compared how serum collected before and after treatment affected cells grown in the lab.
Serum collected after nebivolol produced the most consistent benefits. Exposed cells showed reductions in several markers of senescence, a state in which cells stop dividing. They also had lower levels of a chemical marker of DNA damage. The serum contained less transforming growth factor beta 1, a signaling protein linked to senescence. The authors concluded that nebivolol reduced factors associated with hypertension-related cell senescence by lowering this protein.
Why it matters
Cell senescence connects this work to an aging-biology question: whether blood-pressure drugs can alter circulating signals associated with cells entering a nondividing state.
Caveats
The main findings came from laboratory cells, not evidence of reduced blood-vessel senescence or better health in participants. Participants had not previously taken blood-pressure drugs, and people with secondary hypertension were excluded.
The paper
Poznan University of Medical Sciences; Poznańska Akademia Medyczna Nauk Stosowanych im. Księcia Mieszka I
Journal of Hypertension, Jul 20, 2026, Open access
